drugset
drugset / Trial / NCT03386357

Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT03386357 ↗

Phase 2 Terminated 115 enrolled University of Erlangen-Nürnberg Medical School
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma.

Timeline

Start
2018-07-20
Primary completion
2024-10-01
Completion
2024-10-01

Outcome

Outcome not reported

Stopped (Enrollment): “slow recruitment”

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pembrolizumab Monoclonal antibody 200 mg —

Indications

head and neck squamous cell carcinoma